Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/42318
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorYUKI, Emily Figueiredo Neves-
dc.contributor.authorSILVA, Clovis A.-
dc.contributor.authorAIKAWA, Nadia E.-
dc.contributor.authorROMITI, Ricardo-
dc.contributor.authorHEISE, Carlos Otto-
dc.contributor.authorBONFA, Eloisa-
dc.contributor.authorPASOTO, Sandra Gofinet-
dc.date.accessioned2021-10-20T14:01:28Z-
dc.date.available2021-10-20T14:01:28Z-
dc.date.issued2021-
dc.identifier.citationJCR-JOURNAL OF CLINICAL RHEUMATOLOGY, v.27, n.6, p.248-259, 2021-
dc.identifier.issn1076-1608-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/42318-
dc.description.abstractBackground: Thalidomide has shown exceptional results in systemic/cutaneous lupus erythematosus(SLE/CLE). Recently, lenalidomide has been also prescribed for SLE/CLE treatment. Literature regarding efficacy/adverse events for these drugs is scarce with a single systematic review and meta-analysis focused solely on thalidomide for refractory cutaneous lupus subtypes. Objective: We, therefore, addressed in this narrative review the efficacy/adverse effects of thalidomide and lenalidomide for SLE and CLE. In addition, we provide a specialist approach for clinical practice based on the available evidence. Results: Efficacy of thalidomide for refractory cutaneous lupus treatment was demonstrated by several studies, mostly retrospective with small sample size(<= 20). The frequency of peripheral polyneuropathy is controversial varying from 15-80% with no consistent data regarding cumulative dose and length of use. Drug withdrawn results in clinical partial/complete reversibility for most cases (70%). For lenalidomide, seven studies (small sample sizes) reported its efficacy for SLE/CLE with complete/partial response in all patients with a mean time to response of 3 months. Flare rate varied from 25-75% occurring 0.5-10 months after drug withdrawn. There were no reports of polyneuropathy/worsening of previous thalidomide-induced neuropathy, but most of them did not perform nerve conduction studies. Teratogenicity risk exist for both drugs and strict precautions are required. Conclusions: Thalidomide is very efficacious as an induction therapy for patients with severe/refractory cutaneous lupus with high risk of scarring, but its longstanding use should be avoided due to neurotoxicity. Lenalidomide is a promising drug for skin lupus treatment, particularly regarding the apparent lower frequency of nerve side effects.eng
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/03756-4]-
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e TecnologicoConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [305068/2014-8, 303422/2015-7]-
dc.language.isoeng-
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofJcr-Journal of Clinical Rheumatology-
dc.rightsrestrictedAccesseng
dc.subjectcutaneous lupus erythematosuseng
dc.subjectlenalidomideeng
dc.subjectperipheral neuropathyeng
dc.subjectsystemic lupus erythematosuseng
dc.subjectthalidomideeng
dc.subject.otherlow-dose thalidomideeng
dc.subject.otherinduced peripheral neuropathyeng
dc.subject.othercutaneous lupuseng
dc.subject.otherseverity indexeng
dc.subject.othersensory neurotoxicityeng
dc.subject.other2nd-line treatmenteng
dc.subject.othermultiple-myelomaeng
dc.subject.otherdisease-activityeng
dc.subject.otherrisk-factorseng
dc.subject.othertherapyeng
dc.titleThalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment A Narrative Review of Literature for Clinical Practiceeng
dc.typearticleeng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.identifier.doi10.1097/RHU.0000000000001160-
dc.identifier.pmid31693649-
dc.subject.wosRheumatologyeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
hcfmusp.description.beginpage248-
hcfmusp.description.endpage259-
hcfmusp.description.issue6-
hcfmusp.description.volume27-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000692194300024-
hcfmusp.origem.id2-s2.0-85088867203-
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAlbrecht J, 2005, J INVEST DERMATOL, V125, P889, DOI 10.1111/j.0022-202X.2005.23889.xeng
hcfmusp.relation.referenceAlfadley A, 2003, J AM ACAD DERMATOL, V48, pS89, DOI 10.1067/mjd.2003.149eng
hcfmusp.relation.referenceAnyanwu CO, 2014, JCR-J CLIN RHEUMATOL, V20, P399, DOI 10.1097/RHU.0000000000000176eng
hcfmusp.relation.referenceArmoiry X, 2008, J CLIN PHARM THER, V33, P219, DOI 10.1111/j.1365-2710.2008.00920.xeng
hcfmusp.relation.referenceATRA E, 1993, CLIN EXP RHEUMATOL, V11, P487eng
hcfmusp.relation.referenceBarba Rubio J, 1977, Med Cutan Ibero Lat Am, V5, P279eng
hcfmusp.relation.referenceBaret I, 2015, J DERMATOL TREAT, V26, P173, DOI 10.3109/09546634.2014.906036eng
hcfmusp.relation.referenceBastuji-Garin S, 2002, J INVEST DERMATOL, V119, P1020, DOI 10.1046/j.1523-1747.2002.19502.xeng
hcfmusp.relation.referenceBESSIS D, 1992, LANCET, V339, P549, DOI 10.1016/0140-6736(92)90365-Aeng
hcfmusp.relation.referenceBohmeyer J, 2002, HAUTARZT, V53, P744, DOI 10.1007/s001050100227eng
hcfmusp.relation.referenceBraunstein I, 2012, J AM ACAD DERMATOL, V66, P571, DOI 10.1016/j.jaad.2011.01.015eng
hcfmusp.relation.referenceWienert S, 2008, J DTSCH DERMATOL GES, V6, P214, DOI 10.1111/j.1610-0387.2007.06525.xeng
hcfmusp.relation.referenceWu EY, 2017, LUPUS, V26, P646, DOI 10.1177/0961203316676377eng
hcfmusp.relation.referenceWULFF CH, 1985, BRIT J DERMATOL, V112, P475, DOI 10.1111/j.1365-2133.1985.tb02323.xeng
hcfmusp.relation.referenceYu C, 2013, J AUTOIMMUN, V41, P34, DOI 10.1016/j.jaut.2013.01.007eng
hcfmusp.relation.referenceZara G, 2008, J NEUROL NEUROSUR PS, V79, P1258, DOI 10.1136/jnnp.2008.147892eng
hcfmusp.relation.referenceZeldis JB, 1999, CLIN THER, V21, P319, DOI 10.1016/S0149-2918(00)88289-2eng
hcfmusp.relation.referenceBriani C, 2004, NEUROLOGY, V62, P2288, DOI 10.1212/01.WNL.0000130499.91775.2Ceng
hcfmusp.relation.referenceBrocard A, 2005, ANN DERMATOL VENER, V132, P853, DOI 10.1016/S0151-9638(05)79503-Xeng
hcfmusp.relation.referenceBURROWS NP, 1991, BRIT J DERMATOL, V125, P62, DOI 10.1111/j.1365-2133.1991.tb06042.xeng
hcfmusp.relation.referenceCalabrese L, 2000, AM J MED, V108, P487, DOI 10.1016/S0002-9343(99)00408-8eng
hcfmusp.relation.referenceCavaletti G, 2004, NEUROLOGY, V62, P2291, DOI 10.1212/WNL.62.12.2291eng
hcfmusp.relation.referenceCesbron E, 2018, J AM ACAD DERMATOL, V79, P162, DOI 10.1016/j.jaad.2018.02.049eng
hcfmusp.relation.referenceChasset F, 2018, J AM ACAD DERMATOL, V78, P342, DOI 10.1016/j.jaad.2017.09.059eng
hcfmusp.relation.referenceChaudhry V, 2002, NEUROLOGY, V59, P1872, DOI 10.1212/01.WNL.0000037480.59194.85eng
hcfmusp.relation.referenceChong BF, 2012, BRIT J DERMATOL, V166, P29, DOI 10.1111/j.1365-2133.2011.10610.xeng
hcfmusp.relation.referenceCLEMMENSEN OJ, 1984, ARCH DERMATOL, V120, P338, DOI 10.1001/archderm.120.3.338eng
hcfmusp.relation.referenceCoelho A, 2005, LUPUS, V14, P434, DOI 10.1191/0961203305lu2124oaeng
hcfmusp.relation.referenceCortes-Hernandez J, 2012, BRIT J DERMATOL, V166, P616, DOI 10.1111/j.1365-2133.2011.10693.xeng
hcfmusp.relation.referenceCortes-Hernandez J, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4111eng
hcfmusp.relation.referenceCrouch Rohan B, 2002, Australas J Dermatol, V43, P278, DOI 10.1046/j.1440-0960.2002.00593.xeng
hcfmusp.relation.referenceCuadrado MJ, 2005, AM J MED, V118, P246, DOI 10.1016/j.amjmed.2004.04.030eng
hcfmusp.relation.referenceCundari S, 2009, MINI-REV MED CHEM, V9, P760, DOI 10.2174/138955709788452595eng
hcfmusp.relation.referenceDall'Era MC, 2005, ANN RHEUM DIS, V64, P1692, DOI 10.1136/ard.2004.033753eng
hcfmusp.relation.referenceDanchenko N, 2006, LUPUS, V15, P308, DOI 10.1191/0961203306lu2305xxeng
hcfmusp.relation.referenceDuong DJ, 1999, ARCH DERMATOL, V135, P1079, DOI 10.1001/archderm.135.9.1079eng
hcfmusp.relation.referenceFanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089eng
hcfmusp.relation.referenceFennira F, 2016, J AM ACAD DERMATOL, V74, P1248, DOI 10.1016/j.jaad.2016.01.054eng
hcfmusp.relation.referenceFrankel Hillary C, 2013, Int J Dermatol, V52, P1407, DOI 10.1111/j.1365-4632.2011.05200.xeng
hcfmusp.relation.referenceFULLERTON P, 1961, BMJ-BRIT MED J, V2, P855, DOI 10.1136/bmj.2.5256.855eng
hcfmusp.relation.referenceFULLERTON PM, 1968, J NEUROL NEUROSUR PS, V31, P543, DOI 10.1136/jnnp.31.6.543eng
hcfmusp.relation.referenceGambini D, 2004, J Dermatolog Treat, V15, P365eng
hcfmusp.relation.referenceGARDNERMEDWIN JMM, 1994, ANN RHEUM DIS, V53, P828, DOI 10.1136/ard.53.12.828eng
hcfmusp.relation.referenceGeorgala S, 1998, CLIN EXP DERMATOL, V23, P141eng
hcfmusp.relation.referenceGiannini F, 2003, NEUROLOGY, V60, P877, DOI 10.1212/01.WNL.0000049462.03800.B1eng
hcfmusp.relation.referenceGILLIAM JN, 1981, J AM ACAD DERMATOL, V4, P471, DOI 10.1016/S0190-9622(81)80261-7eng
hcfmusp.relation.referenceGladman D, 1996, ARTHRITIS RHEUM, V39, P363, DOI 10.1002/art.1780390303eng
hcfmusp.relation.referenceGladman DD, 2002, J RHEUMATOL, V29, P288eng
hcfmusp.relation.referenceGuissa VR, 2012, ACTA REUMATOL PORT, V37, P82eng
hcfmusp.relation.referenceHAFSTROM T, 1967, ACTA NEUROL SCAND, VS 43, P5eng
hcfmusp.relation.referenceHARLAND CC, 1995, EUR J CLIN PHARMACOL, V49, P1eng
hcfmusp.relation.referenceHASPER MF, 1983, ARCH DERMATOL, V119, P812, DOI 10.1001/archderm.119.10.812eng
hcfmusp.relation.referenceHESS CW, 1986, J NEUROL, V233, P83, DOI 10.1007/BF00313852eng
hcfmusp.relation.referenceHOLM AL, 1993, ARCH DERMATOL, V129, P1548, DOI 10.1001/archderm.129.12.1548eng
hcfmusp.relation.referenceHousman TS, 2003, ARCH DERMATOL, V139, P50, DOI 10.1001/archderm.139.1.50eng
hcfmusp.relation.referenceHughes RAC, 2002, BRIT MED J, V324, P466, DOI 10.1136/bmj.324.7335.466eng
hcfmusp.relation.referenceIsoardo G, 2004, ACTA NEUROL SCAND, V109, P188, DOI 10.1034/j.1600-0404.2003.00203.xeng
hcfmusp.relation.referenceJarukitsopa S, 2015, ARTHRIT CARE RES, V67, P817, DOI 10.1002/acr.22502eng
hcfmusp.relation.referenceJimenez S, 2004, CUT LUP ER, P33eng
hcfmusp.relation.referenceJohnson DC, 2011, J CLIN ONCOL, V29, P797, DOI 10.1200/JCO.2010.28.0792eng
hcfmusp.relation.referenceJolly M, 2013, J AM ACAD DERMATOL, V68, P618, DOI 10.1016/j.jaad.2012.08.035eng
hcfmusp.relation.referenceKindle SA, 2016, INT J DERMATOL, V55, pE431, DOI 10.1111/ijd.13226eng
hcfmusp.relation.referenceKNOP J, 1983, BRIT J DERMATOL, V108, P461, DOI 10.1111/j.1365-2133.1983.tb04600.xeng
hcfmusp.relation.referenceKrathen MS, 2008, ARTHRIT RHEUM-ARTHR, V59, P338, DOI 10.1002/art.23319eng
hcfmusp.relation.referenceKuhn A, 2017, J EUR ACAD DERMATOL, V31, P389, DOI 10.1111/jdv.14053eng
hcfmusp.relation.referenceKuhn A, 2011, J AM ACAD DERMATOL, V65, P54, DOI [10.1016/j.jaad.2010.03.037, 10.1016/j.jaad.2010.06.018, 10.1016/j.jaad.2010.06.017]eng
hcfmusp.relation.referenceKyriakis KP, 2000, INT J DERMATOL, V39, P218, DOI 10.1046/j.1365-4362.2000.00953.xeng
hcfmusp.relation.referenceLAGUENY A, 1986, MUSCLE NERVE, V9, P837, DOI 10.1002/mus.880090907eng
hcfmusp.relation.referenceLiew WKM, 2016, J PEDIATR-US, V178, P227, DOI 10.1016/j.jpeds.2016.07.040eng
hcfmusp.relation.referenceLu KQ, 2003, PHOTODERMATOL PHOTO, V19, P272, DOI 10.1046/j.1600-0781.2003.00055.xeng
hcfmusp.relation.referenceLuczkowska K, 2018, J PHYSIOL PHARMACOL, P69eng
hcfmusp.relation.referenceLuo J, 2017, EUR J CANCER, V70, P22, DOI 10.1016/j.ejca.2016.10.018eng
hcfmusp.relation.referenceLyakhovisky Anna, 2006, Harefuah, V145, P489eng
hcfmusp.relation.referenceMa CY, 2012, RHEUMATOL INT, V32, P395, DOI 10.1007/s00296-010-1636-6eng
hcfmusp.relation.referenceMolloy FM, 2001, MUSCLE NERVE, V24, P1050, DOI 10.1002/mus.1109eng
hcfmusp.relation.referenceNAAFS B, 1982, BRIT J DERMATOL, V107, P83, DOI 10.1111/j.1365-2133.1982.tb00294.xeng
hcfmusp.relation.referenceNAAFS B, 1985, INT J DERMATOL, V24, P131, DOI 10.1111/j.1365-4362.1985.tb05400.xeng
hcfmusp.relation.referenceNakamura T, 2007, CHEM PHARM BULL, V55, P651, DOI 10.1248/cpb.55.651eng
hcfmusp.relation.referenceOCHONISKY S, 1994, ARCH DERMATOL, V130, P66, DOI 10.1001/archderm.130.1.66eng
hcfmusp.relation.referenceOkon L, 2014, J AM ACAD DERMATOL, V70, P583, DOI 10.1016/j.jaad.2013.11.007eng
hcfmusp.relation.referenceOrdi-Ros J, 2000, J RHEUMATOL, V27, P1429eng
hcfmusp.relation.referencePetersen MP., 2018, LUPUS, V27, P1424, DOI [10.1177/0961203318777103, DOI 10.1177/0961203318777103]eng
hcfmusp.relation.referencePons-Estel BA, 2018, ANN RHEUM DIS, V77, P1549, DOI 10.1136/annrheumdis-2018-213512eng
hcfmusp.relation.referencePrommer EE, 2011, J PAIN SYMPTOM MANAG, V41, P140, DOI 10.1016/j.jpainsymman.2010.10.001eng
hcfmusp.relation.referenceReefman E, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2051eng
hcfmusp.relation.referenceRichardson P, 2009, BLOOD, V114, P772, DOI 10.1182/blood-2008-12-196238eng
hcfmusp.relation.referenceRuiz H, 1999, AM J DERMATOPATH, V21, P356, DOI 10.1097/00000372-199908000-00008eng
hcfmusp.relation.referenceSAMSOEN M, 1980, ANN DERMATOL VENER, V107, P515eng
hcfmusp.relation.referenceSato E I, 1998, Rev Assoc Med Bras (1992), V44, P289, DOI 10.1590/S0104-42301998000400007eng
hcfmusp.relation.referenceSCOLARI F, 1982, DERMATOLOGICA, V165, P355, DOI 10.1159/000249960eng
hcfmusp.relation.referenceShah A, 2009, ARCH DERMATOL, V145, P303, DOI 10.1001/archdermatol.2009.30eng
hcfmusp.relation.referenceSharma NL, 2007, J DERMATOL TREAT, V18, P335, DOI 10.1080/09546630701386993eng
hcfmusp.relation.referenceSigges J, 2013, AUTOIMMUN REV, V12, P694, DOI 10.1016/j.autrev.2012.10.005eng
hcfmusp.relation.referenceStevens RJ, 1997, BRIT J RHEUMATOL, V36, P353eng
hcfmusp.relation.referenceSTOKES PA, 1976, EXPERIENTIA, V32, P597, DOI 10.1007/BF01990184eng
hcfmusp.relation.referenceTebbe B, 1997, LUPUS, V6, P96, DOI 10.1177/096120339700600204eng
hcfmusp.relation.referenceThomson KF, 2001, J DERMATOL TREAT, V12, P145eng
hcfmusp.relation.referenceTseng S, 1996, J AM ACAD DERMATOL, V35, P969, DOI 10.1016/S0190-9622(96)90122-Xeng
hcfmusp.relation.referenceUS Food and Drug Administration, LENeng
hcfmusp.relation.referenceVersapuech J, 2000, PRESSE MED, V29, P1596eng
hcfmusp.relation.referenceWalchner M, 2000, INT J DERMATOL, V39, P383, DOI 10.1046/j.1365-4362.2000.00866.xeng
hcfmusp.relation.referenceWang DD, 2016, CLIN RHEUMATOL, V35, P1521, DOI 10.1007/s10067-016-3256-3eng
hcfmusp.relation.referenceWarren KJ, 1998, J AM ACAD DERMATOL, V39, P293, DOI 10.1016/S0190-9622(98)70096-9eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1536-7355-
hcfmusp.citation.scopus6-
hcfmusp.scopus.lastupdate2022-09-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - FM/MPE
Departamento de Pediatria - FM/MPE

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/ICr
Instituto da Criança - HC/ICr

Artigos e Materiais de Revistas Científicas - HC/IOT
Instituto de Ortopedia e Traumatologia - HC/IOT

Artigos e Materiais de Revistas Científicas - LIM/03
LIM/03 - Laboratório de Medicina Laboratorial

Artigos e Materiais de Revistas Científicas - LIM/15
LIM/15 - Laboratório de Investigação em Neurologia

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia

Artigos e Materiais de Revistas Científicas - LIM/36
LIM/36 - Laboratório de Pediatria Clínica

Artigos e Materiais de Revistas Científicas - LIM/50
LIM/50 - Laboratório de Patologia das Moléstias Infecciosas


Files in This Item:
File Description SizeFormat 
art_YUKI_Thalidomide_and_Lenalidomide_for_Refractory_SystemicCutaneous_Lupus_Erythematosus_2021.PDF
  Restricted Access
publishedVersion (English)257.46 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.